The clinical efficacy of Cetuximab in treating gastrointestinal malignant tumor

doi:10.3877/cma.j.issn.2095-3224.2014.03.06

Abstract

Abstract:

Objective

To explore the clinical efficacy of avastin combined with chemotherapy in the treatment of gastrointestinal cancer.

Methods

82 elderly patients with gastrointestinal cancer were randomly divided into observation group and control group.There were 41 cases in each group.The control group was given conventional FOLFOX4 chemotherapy, while the observation group was given the monoclonal antibody Avastin in the basis of the FOLFOX4 chemotherapy.The clinical efficacy and the incidence of adverse reactions were observed.

Results

In the observation group, the clinical efficiency was 58.1%, the clinical symptom control rate was 88.4%, the cancer cell apoptosis rate was 27.3±2.83%.While in the control group, the clinical efficiency was 58.1%, the clinical symptom control rate was 88.4%, the cancer cell apoptosis rate was 27.3±2.83%.There were significant differences between the two groups in the above indicators(P<0.05). However, the incidence of toxic reaction did not show significant difference between the two groups(P>0.05).

Conclusion

Cetuximab can significantly improve the clinical efficacy in the treatment of gastrointestinal malignant tumors.

Key words: Neoplasms, second primary, Observation, Molecular mechanisms of pharmacological action, Cetuximab therapy

Lei WANG, Xi-ling BAI, Dao-qi ZHU. The clinical efficacy of Cetuximab in treating gastrointestinal malignant tumor[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2014, 03(03): 185-188.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2014.03.06

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2014/V03/I03/185

Figures/Tables 3

References 16

[1]	吴开春,陈蓓. 胃癌靶向治疗的分子基础. 西安交通大学学报(医学版), 2009, 30(5): 523-527.
[2]	王珏辉,郭宇红,张红新, 等. 血管内皮细胞生长因子与P53在卵巢上皮性肿瘤中表达的定量分析. 现代预防医学, 2010, 37(10): 1859-1860.
[3]	陈秀美.45例胃癌患者临床和组织学分类的检验分析. 检验医学和临床, 2012, 9(11): 1341-1342.
[4]	肖子理,沈志勇,倪醒之. 胃癌的分子靶向治疗研究进展. 实用医学杂志, 2009, 25(14): 2207-2209.
[5]	Tang H,Wang J,Bai F, et al.Positive correlation of osteopontin, cyclooxygenase－2 and vascular endothelial growth factor in gastric cancer.Cancer Invest, 2008, 26(1): 60-67.
[6]	邱寿庆. 肿瘤化疗致呕吐140例因素分析与临床干预. 中国老年学杂志, 2011, 31(11): 2102-2103.
[7]	陈丽花. 妇科恶性肿瘤患者生存质量及相关因素调查. 现代预防医学, 2011, 38(13): 2485-2486.
[8]	Saltz LB,Clarke S,Díaz－Rubio E, et al.Bevacizumab in combination with oxaliplatin－based chemotherapy as first－line therapy in metastatic colorectal cancer：a randomized phase III study.Journal of Clinical Oncology, 2008, 26(12): 2013-2019.
[9]	Van Cutsem E,Peeters M,Siena S, et al.Open－label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy－ refractory metastatic colorectal cancer.Journal of Clinical Oncology, 2007, 25(13): 1658-1664.
[10]	郭本成. 奥沙利铂联合替吉奥胶囊治疗晚期胃癌的临床效果. 检验医学和临床, 2013, 10(15): 2016-2017.
[11]	方骏,孟翔凌. 老年胃癌手术139例近期并发症分析. 中国老年学杂志, 2011, 31(4): 686-687.
[12]	Bhuvaneswari R,Yuen GY,Chee SK, et al.Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.Lasers in Surgery and Medicine, 2011, 43(7): 651-662.
[13]	Li J,Merl MY,Saif MW.Any second－line the rapy for advanced pancreatic cancer highlights from the "2010 ASCO Gastrointestinal Cancers Symposium" . Pancreas(Online), 2010, 11(2): 151-153.
[14]	Shi L,Chen J,Yang J, et al.MiR－21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl－2 ratio and caspase－3 activity.Brain research, 2010, 1352: 255-264.
[15]	梁荣祥,李苏萌. 恶性肿瘤的分子靶向治疗. 山东医药, 2010, 50(1): 104-105.
[16]	Piatrouskaya NA,Kharuzhyk SA,Vozmitel MA, et al.Experimental study of antiangiogenic and photodynamic therapies combination for treatment of peritoneal carcinomatosis：preliminary results.Experimental Oncology, 2010, 32(2): 100-103.

组别	例数	凋亡率(%)	CR	PR	SD	PD	DCR(%)	RR(%)
对照组	41	23.9±2.45	3	11	14	13	68.2	34.1
观察组	41	27.3±2.83^a	9^a	16^a	12	4^*	90.2^a	60.9^a

组别	例数	凋亡率(%)	CR	PR	SD	PD	DCR(%)	RR(%)
对照组	41	23.9±2.45	3	11	14	13	68.2	34.1
观察组	41	27.3±2.83^a	9^a	16^a	12	4^*	90.2^a	60.9^a

组别	例数	QLQ－STO22问卷评分		KPS评分
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	41	53.34±4.76	44.57±5.21	65.1±1.9	67.9±1.9
观察组	41	54.21±4.09	24.03±3.58^ab	63.8±2.7	78.1±2.2^ab

组别	例数	QLQ－STO22问卷评分		KPS评分
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	41	53.34±4.76	44.57±5.21	65.1±1.9	67.9±1.9
观察组	41	54.21±4.09	24.03±3.58^ab	63.8±2.7	78.1±2.2^ab

组别	级别	贫血	粘膜炎	腹泻	白细胞减少	脱发	肝肾功能异常	恶心呕吐	感染
?	0级	20	18	17	19	11	22	14	15
?	Ⅰ－Ⅱ级	10	10	7	13	6	13	7	17
观察组	Ⅲ级	9	8	10	6	15	5	17	9
?	Ⅳ级	2	5	7	3	9	1	3	0
?	发生率(%)	26.8%^*	31.7%^*	41.5%^*	21.9%^*	58.5%^*	14.6%^*	48.8%^*	21.9%^*
?	0级	19	17	13	23	8	24	11	17
?	Ⅰ－Ⅱ级	12	12	10	10	7	12	8	13
对照组	Ⅲ级	7	9	12	5	16	4	15	10
?	Ⅳ级	3	3	6	3	10	1	7	1
?	发生率(%)	24.4%	29.3%	43.9%	19.5%	63.4%	12.2%	53.7%	26.8%

Please choose a citation manager

Content to export